Atypical patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in patients with chronic myeloid leukemia

被引:0
作者
Jardan, Cerasela [1 ,2 ]
Jardan, Dumitru [2 ]
Coriu, Daniel [2 ]
Severin, Emilia [2 ]
机构
[1] Fundeni Clin Inst, Dept Hematol, Bucharest, Romania
[2] Carol Davila Univ Med & Pharm Bucharest, Bucharest, Romania
来源
REVISTA ROMANA DE MEDICINA DE LABORATOR | 2012年 / 20卷 / 03期
关键词
peripheral blood-FISH technique; BCR/ABL gene fusion; minimal residual disease; CHRONIC MYELOGENOUS LEUKEMIA; POOR-PROGNOSIS; THERAPY; BREAKPOINT; DELETIONS; SUBGROUP; CML;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Fluorescent in situ hybridization (FISH) technique is increasingly used for the identification of BCR/ABL gene rearrangements in chronic myeloid leukemia (CML).Patients and Methods: Both typical and atypical pattern of BCR/ABL gene rearrangenzents was determined in 83 patients with CML referred to Fundeni Clinical Institute using dual fusion fluorescence in situ hybridization (DF-FISH) probes and conventional cytogenetics.Results: in the majority of cases - 82 out of 83- CML patients exhibited a translocation between chromosome 9 and 22, resulting in a Philadelphia chromosome and one patient, negative for the Ph chromosome, presented cryptic BCR/ABL rearrangement. All samples were analyzed both by FISH and conventional cytogenetics. In 71 out of 83 cases the typical interphase FISH signal patterns of BCR/ABL gene rearrangements was identified one red signal, one green signal and two fusion signals (1R1G2F). The rest of I I patients presented an atypical interphase FISH pattern. Atypical patterns included: loss of terminal region of derivative chromosome 9 (five patients), loss of derivative chromosome 9 (del(9q)der) (three patients), isodicentric 22 derivative chromosome fused at terminal region of q arm (one patient), isoderivative chromosomes 22 (ider(22)t(9:22) (q34;q11)) (one patient) and supernumerary Philadelphia (one patient).Conclusion: FISH technique exhibited an advantage of being simple and still allowing the identification of cryptic BCR-ABL insertion or variant Ph. Another advantage of this technique is that it allows examination of interphase nuclei in cases were no metaphases could be obtained and atypical patterns may have clinical prognostic implication.
引用
收藏
页码:69 / 77
页数:9
相关论文
共 17 条
  • [1] BCR REARRANGEMENT IN PH-NEGATIVE CML
    BARTRAM, CR
    CARBONELL, F
    [J]. CANCER GENETICS AND CYTOGENETICS, 1986, 21 (02) : 183 - 184
  • [2] Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party Analysis
    Castagnetti, Fausto
    Testoni, Nicoletta
    Luatti, Simona
    Marzocchi, Giulia
    Mancini, Marco
    Kerim, Simonetta
    Giugliano, Emilia
    Albano, Francesco
    Cuneo, Antonio
    Abruzzese, Elisabetta
    Martino, Bruno
    Palandri, Francesca
    Amabile, Marilina
    Iacobucci, Ilaria
    Alimena, Giuliana
    Pane, Fabrizio
    Martinelli, Giovanni
    Saglio, Giuseppe
    Baccarani, Michele
    Rosti, Gianantonio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2748 - 2754
  • [3] Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene:: expression profiling, resistance to interferon therapy, and poor prognosis
    Cohen, N
    Rozenfeld-Granot, G
    Hardan, I
    Brok-Simoni, F
    Amariglio, N
    Rechavi, G
    Trakhtenbrot, L
    [J]. CANCER GENETICS AND CYTOGENETICS, 2001, 128 (02) : 114 - 119
  • [4] Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia
    Dewald, GW
    Wyatt, WA
    Juneau, AL
    Carlson, RO
    Zinsmeister, AR
    Jalal, SM
    Spurbeck, JL
    Silver, RT
    [J]. BLOOD, 1998, 91 (09) : 3357 - 3365
  • [5] GANESAN TS, 1986, BLOOD, V68, P957
  • [6] Gozzetti A, 2000, SEMIN HEMATOL, V37, P320, DOI 10.1016/S0037-1963(00)90013-1
  • [7] Itoh T, 1999, INT J MOL MED, V4, P659
  • [8] Lim TH, 2005, ANN ACAD MED SINGAP, V34, P533
  • [9] Lisa G, 2009, ISCN 2009 INT SYSTEM
  • [10] Melo JV, 1996, LEUKEMIA, V10, P751